Sanofi-aventis And Bristol-Myers Squibb Back NICE’s Decision To Review Guidance On Vascular Disease - New Evidence Could Affect Change In Guidance, UK
August 18th, 2008 by 
admin Sanofi-aventis and Bristol-Myers Squibb backwards today’s selection by NICE (the National Institute for Health and Clinical Excellence) to analyse its counselling on tube disease for clopidogrel (Plavix®) and dipyridamole. NICE originally designed to defer analyse of the guidance, titled Technology Appraisal Number 90 (TAG90), until Nov 2010. During the past NICE conference process, a sort of organisations, highlighted the imperative requirement for an early review.
Posted in Cardiology | 